Forging a New Path in Neovascular Retinal Disease: Novel Targets for More Durable Treatment

Forging a New Path in Neovascular Retinal Disease: Novel Targets for More Durable Treatment is organized by Paradigm Medical Communications, LLC.,Release Date: August 25, 2022,Expiration Date: August 25, 2023,Program Overview:,An enhanced understanding of neovascular retina disease pathophysiology has led to the development of groundbreaking therapy targeting pathways beyond vascular endothelial growth factor A (VEGF-A). Faricimab, the first and only agent that targets 2 pathways, allows for unprecedented treatment durability (up to 16 weeks) and enhanced disease control versus conventional anti-VEGF (every 8 weeks). Join experts on a multimedia exploration of the pivotal data on which faricimab’s recent FDA approval was based and real-life patients who have benefited so far.,Learning Objectives:,Upon completion of this activity, participants should be able to:,• Identify components of neovascular retinal disease pathophysiology other than VEGF-A that are targets of novel therapies,• Evaluate clinical trial designs, safety, and efficacy of novel strategies developed to provide more durable treatment of neovascular retinal diseases,• Individualize the treatment of patients with neovascular retinal diseases based on evidence and with consideration of patient’s clinical needs and preferences.